Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bert Bammens

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Kidney International Reports|August 15, 2025
The Double-Icodextrin Dose Randomized Controlled Trial of a Double Icodextrin Dose for Older Patients on Incremental Continuous Ambulatory Peritoneal DialysisEric Goffin, Clémence Béchade, Cécile Courivaud, et al.
Pediatric Nephrology (Berlin, Germany)|February 1, 2025
Characteristics of patients with autosomal polycystic kidney disease reaching kidney failure by age 40Stijn Wigerinck, Pieter Schellekens, Byron H Smith, et al.
Kidney International Reports|December 22, 2025
Erratum to "Randomized Controlled Trial of a Double Icodextrin Dose for Older Patients on Incremental Continuous Ambulatory Peritoneal Dialysis" [<i>Kidney International Reports</i> Volume 10, Issue 8, August 2025, Pages 2585-2596]Eric Goffin, Clémence Béchade, Cécile Courivaud, et al.
The New England Journal of Medicine|November 8, 2013
Intrarenal resistive index after renal transplantationMaarten Naesens, Line Heylen, Evelyne Lerut, et al.
BMC Nephrology|June 3, 2025
Addressing the inequity of access to home Dialysis in Europe: recommendations for action informed by an international consensus exerciseSimon J Davies, Bert Bammens, Ilaria de Barbieri, et al.
Kidney International Reports|June 25, 2021
Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney DiseasePeter Janssens, Jean-Paul Decuypere, Stéphanie De Rechter, et al.
Trials|February 14, 2024
HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trialThomas Bais, Esther Meijer, Bart J Kramers, et al.
The New England Journal of Medicine|October 20, 2021
<i>AQP1</i> Promoter Variant, Water Transport, and Outcomes in Peritoneal DialysisJohann Morelle, Céline Marechal, Zanzhe Yu, et al.
Scientific Reports|May 30, 2019
Clinical courses and complications of young adults with Autosomal Recessive Polycystic Kidney Disease (ARPKD)Kathrin Burgmaier, Samuel Kilian, Bert Bammens, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Kidney International Reports|August 15, 2025
The Double-Icodextrin Dose Randomized Controlled Trial of a Double Icodextrin Dose for Older Patients on Incremental Continuous Ambulatory Peritoneal DialysisEric Goffin, Clémence Béchade, Cécile Courivaud, et al.
Pediatric Nephrology (Berlin, Germany)|February 1, 2025
Characteristics of patients with autosomal polycystic kidney disease reaching kidney failure by age 40Stijn Wigerinck, Pieter Schellekens, Byron H Smith, et al.
Kidney International Reports|December 22, 2025
Erratum to "Randomized Controlled Trial of a Double Icodextrin Dose for Older Patients on Incremental Continuous Ambulatory Peritoneal Dialysis" [<i>Kidney International Reports</i> Volume 10, Issue 8, August 2025, Pages 2585-2596]Eric Goffin, Clémence Béchade, Cécile Courivaud, et al.
The New England Journal of Medicine|November 8, 2013
Intrarenal resistive index after renal transplantationMaarten Naesens, Line Heylen, Evelyne Lerut, et al.
BMC Nephrology|June 3, 2025
Addressing the inequity of access to home Dialysis in Europe: recommendations for action informed by an international consensus exerciseSimon J Davies, Bert Bammens, Ilaria de Barbieri, et al.
Kidney International Reports|June 25, 2021
Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney DiseasePeter Janssens, Jean-Paul Decuypere, Stéphanie De Rechter, et al.
Trials|February 14, 2024
HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trialThomas Bais, Esther Meijer, Bart J Kramers, et al.
The New England Journal of Medicine|October 20, 2021
<i>AQP1</i> Promoter Variant, Water Transport, and Outcomes in Peritoneal DialysisJohann Morelle, Céline Marechal, Zanzhe Yu, et al.
Scientific Reports|May 30, 2019
Clinical courses and complications of young adults with Autosomal Recessive Polycystic Kidney Disease (ARPKD)Kathrin Burgmaier, Samuel Kilian, Bert Bammens, et al.
Pageof 10